(redirected from androgen deprivation)
Also found in: Dictionary, Thesaurus, Medical, Legal.
Related to androgen deprivation: Androgen Deprivation Therapy


the lack of economic and emotional supports generally accepted as basic essentials of human experience. These include income and housing, and parental care (or an adequate substitute) for children. This recognizes that care, shelter and security are human needs (see also HUMANISTIC PSYCHOLOGY, MASLOW) the possession of which leads to a fuller, more comfortable life experience and allows a more complete development of the individual's potential. See also CYCLE OF DEPRIVATION, POVERTY, RELATIVE DEPRIVATION.
Collins Dictionary of Sociology, 3rd ed. © HarperCollins Publishers 2000
The following article is from The Great Soviet Encyclopedia (1979). It might be outdated or ideologically biased.



sensory insufficiency or inadequate load on the system of analysors observed in man when isolated or when the functioning of the main sense organs is impaired. Astronauts, speleologists, and others experience the phenomenon of deprivation. The depth of the psychological, autonomic, and somatic changes in deprivation is determined chiefly by its intensity and duration, as well as by individual personality traits. If work capacity and mental health are to be retained under conditions of deprivation, it is very important that the work be organized efficiently and that specific steps be taken to increase the reliability of the auditory, visual, interoceptive, and other information.


Banshchikov, V. M., and G. V. Stoliarov. “Sensornaia izoliatsiia.” Zhurnal nevropatologii ipsikhiatrii im. S. S. Korsakova, 1966, no. 9, pp. 1428–40.
The Great Soviet Encyclopedia, 3rd Edition (1970-1979). © 2010 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
TROG 03.06 and VCOG PR 01-03: The << Timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD) >> collaborative randomised phase III trial.
Key differences between GETUG-AFU 15 and ECOG 3805 studies GETUG ECOG Total sample size 385 790 High-volume 183 (47.5%) 514 (65%) disease Median follow-up 83 months 29 months Received ADT-only arm: 80% ADT-only arm: 33% post-protocol docetaxel ADT-docetaxel arm: 45% ADT-docetaxel arm: 12% Received ADT-only arm: ADT-only arm: 20% post-protocol No response abiraterone or ADT-docetaxel arm: 23% enzalutamide ADT-docetaxel arm: No response GETUG-AFU: Groupe d'Etude des Tumeurs Uro-Genital-Association Francaise d'Urologie; ECOG: Eastern Cooperative Oncology Group; ADT: androgen deprivation therapy.
In patients with high-grade tumours, long-term androgen deprivation (2 to 3 years) has been associated with improved survival compared to short-term treatment.[sup.13]-[sup.15] Therefore, an understanding of the patient's risk of true high-grade cancer may help inform the optimal duration of androgen deprivation, and may provide the patient with a more accurate assessment of post-treatment prognosis.
While patients taking androgen deprivation therapy (ADT) may be justifiably focused on their prostate cancer, it is important they, their families and their physicians, be aware that cardiovascular (CV) morbidity and mortality remain important considerations.
Hot flashes and night sweats are frequent side effects in men who undergo palliative androgen deprivation therapy.
None of the patients had nodal disease or received neoadjuvant androgen deprivation, which had a median follow-up of 48 months.
The study results have shown that abiraterone acetate plus prednisone, in combination with androgen deprivation therapy, decreased the risk of death by 38% compared against placebo plus androgen deprivation therapy.
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610.
None of the patients had nodal disease or received neoadjuvant androgen deprivation in the study, which had a median follow-up of 48 months.
They are members of a multicenter team that has completed the largest study so far on the impact of androgen deprivation on bone.
The partnership will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in metastatic hormone sensitive prostate cancer (mHSPC) patients.
Osteoporotic fractures are common in men, particularly in men undergoing androgen deprivation therapy (ADT) for prostate cancer treatment.

Full browser ?